Early February, AUA staff attended the annual meeting of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as Friends of NIDDK. At the meeting, representatives from NIDDK discussed their commitment to combating racial and ethnic disparities, their focus on patient-centered outcomes and their response to the COVID-19 emergency. They spoke of advancements in kidney research including a new technology to move kidney stones through the body using an ultrasound technique, as well as a novel study that demonstrated small-molecule inhibitors can restore telomerase activities in patient stem cells. NIDDK’s most immediate concern was COVID-19’s effect on existing clinical trials, and they expressed the need for more funding in order to restore this important research. NIDDK received an $18 million increase in their budget in Fiscal Year (FY) 2021, but a similar increase in FY 2022 may not be enough to combat the effects of COVID-19.